{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:57:26Z","timestamp":1786982246119,"version":"build-2736575974"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Advances in surgical procedures and immunosuppressive therapies have considerably improved the outcomes of patients who have undergone liver transplantation in the past few decades. In 2020, the Italian Liver Transplant Working Group published practice-oriented algorithms for immunosuppressive therapy (IT) in adult liver transplant (LT) recipients. Due to the rapidly evolving LT field, regular updates to the recommendations are required. This review presents a consensus- and evidence-based update of the 2020 recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Italian Liver Transplant Working Group set out to address new IT issues, which were discussed based on supporting literature and the specialists\u2019 personal experiences. The panel deliberated on and graded each statement before consensus was reached.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A series of consensus statements were formulated and finalized on: (i) oncologic indications for LT; (ii) management of chronic LT rejection; (iii) combined liver\u2013kidney transplantation; (iv) immunosuppression for transplantation with an organ donated after circulatory death; (v) transplantation in the presence of frailty and sarcopenia; and (vi) ABO blood group incompatibility between donor and recipient. Algorithms were updated in the following LT groups: standard patients, critical patients, oncology patients, patients with specific etiology, and patients at high immunologic risk. A steroid-free approach was generally recommended, except for patients with autoimmune liver disease and those at high immunologic risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The updated consensus- and evidence-based 2024 recommendations for immunosuppression regimens in adult patients with ABO-compatible LT address a range of clinical variables that should be considered to optimize the choice of the immunosuppression treatment in clinical practice in Italy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s12072-024-10703-4","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T13:01:56Z","timestamp":1721048516000},"page":"1416-1430","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Immunosuppression in adult liver transplant recipients: a 2024 update from the Italian Liver Transplant Working Group"],"prefix":"10.1007","volume":"18","author":[{"given":"Tommaso Maria","family":"Manzia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amedeo","family":"Carraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Guglielmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lauterio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mameli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Cillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"De Carlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Del Gaudio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8308-0701","authenticated-orcid":false,"given":"Stefano","family":"Fagiuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Lupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Tisone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Volpes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Italian Liver Transplant Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,15]]},"reference":[{"key":"10703_CR1","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000515933","volume":"106","author":"A Karolin","year":"2021","unstructured":"Karolin A, Genitsch V, Sidler D. Calcineurin inhibitor toxicity in solid organ transplantation. Pharmacology. 2021;106:347\u2013355","journal-title":"Pharmacology"},{"key":"10703_CR2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/TP.0000000000001438","volume":"101","author":"P De Simone","year":"2017","unstructured":"De Simone P, Fagiuoli S, Cescon M, De Carlis L, Tisone G, Volpes R, et al. Use of everolimus in liver transplantation: recommendations from a Working Group. Transplantation. 2017;101:239\u2013251","journal-title":"Transplantation"},{"key":"10703_CR3","doi-asserted-by":"crossref","first-page":"990","DOI":"10.4254\/wjh.v9.i23.990","volume":"9","author":"ML Yee","year":"2017","unstructured":"Yee ML, Tan HH. Use of everolimus in liver transplantation. World J Hepatol. 2017;9:990\u20131000","journal-title":"World J Hepatol"},{"key":"10703_CR4","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1097\/TP.0000000000003394","volume":"105","author":"SG Lee","year":"2021","unstructured":"Lee SG, Jeng LB, Saliba F, Singh Soin A, Lee WC, De Simone P, et al. Efficacy and safety of everolimus with reduced tacrolimus in liver transplant recipients: 24-month results from the pooled analysis of 2 randomized controlled trials. Transplantation. 2021;105:1564\u20131575","journal-title":"Transplantation"},{"key":"10703_CR5","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s12072-020-10091-5","volume":"14","author":"U Cillo","year":"2020","unstructured":"Cillo U, De Carlis L, Del Gaudio M, De Simone P, Fagiuoli S, Lupo F, et al. Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group. Hepatol Int. 2020;14:930\u2013943","journal-title":"Hepatol Int"},{"key":"10703_CR6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Sch\u00fcnemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3 rating the quality of evidence. J Clin Epidemiol. 2011;64:401\u2013406","journal-title":"J Clin Epidemiol"},{"key":"10703_CR7","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/tri.13358","volume":"31","author":"R Adam","year":"2018","unstructured":"Adam R, Karam V, Cailliez V, Mirza D, Cherqui D, Klempnauer J, et al. 2018 Annual Report of the European Liver Transplant Registry (ELTR) - 50-year evolution of liver transplantation. Transpl Int. 2018;31:1293\u20131317","journal-title":"Transpl Int"},{"key":"10703_CR8","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2468-1253(18)30045-1","volume":"3","author":"KE Lunsford","year":"2018","unstructured":"Lunsford KE, Javle M, Heyne K, Shroff RT, Abdel-Wahab R, Gupta N, et al. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol. 2018;3:337\u2013348","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10703_CR9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1055\/s-2004-828896","volume":"24","author":"JK Heimbach","year":"2004","unstructured":"Heimbach JK, Gores GJ, Haddock MG, Alberts SR, Nyberg SL, Ishitani MB, et al. Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis. 2004;24:201\u2013207","journal-title":"Semin Liver Dis"},{"key":"10703_CR10","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1111\/ajt.15377","volume":"19","author":"S Iesari","year":"2019","unstructured":"Iesari S, Mocchegiani F, Nicolini D, Benedetti Cacciaguerra A, Coletta M, Montalti R, et al. Liver transplantation for metastatic wild-type gastrointestinal stromal tumor in the era of molecular targeted therapies: report of a first case. Am J Transplant. 2019;19:2939\u20132943","journal-title":"Am J Transplant"},{"key":"10703_CR11","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1111\/ajt.13831","volume":"16","author":"V Mazzaferro","year":"2016","unstructured":"Mazzaferro V, Sposito C, Coppa J, Miceli R, Bhoori S, Bongini M, et al. The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors. Am J Transplant. 2016;16:2892\u20132902","journal-title":"Am J Transplant"},{"key":"10703_CR12","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/bjs.10769","volume":"105","author":"S Dueland","year":"2018","unstructured":"Dueland S, Foss A, Solheim JM, Hagness M, Line PD. Survival following liver transplantation for liver-only colorectal metastases compared with hepatocellular carcinoma. Br J Surg. 2018;105:736\u2013742","journal-title":"Br J Surg"},{"key":"10703_CR13","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/bjs5.50278","volume":"4","author":"TM Smedman","year":"2020","unstructured":"Smedman TM, Line PD, Hagness M, Syversveen T, Grut H, Dueland S. Liver transplantation for unresectable colorectal liver metastases in patients and donors with extended criteria (SECA-II arm D study). BJS Open. 2020;4:467\u2013477","journal-title":"BJS Open"},{"key":"10703_CR14","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ejca.2005.02.004","volume":"41","author":"P Czauderna","year":"2005","unstructured":"Czauderna P, Otte JB, Aronson DC, Gauthier F, Mackinlay G, Roebuck D, et al. Guidelines for surgical treatment of hepatoblastoma in the modern era\u2013recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL). Eur J Cancer. 2005;41:1031\u20131036","journal-title":"Eur J Cancer"},{"key":"10703_CR15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cell.2017.03.035","volume":"169","author":"RA Saxton","year":"2017","unstructured":"Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;169:361\u2013371","journal-title":"Cell"},{"key":"10703_CR16","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/ajt.15697","volume":"20","author":"EC Verna","year":"2020","unstructured":"Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, Pillai AA, et al. Liver transplantation for hepatocellular carcinoma: management after the transplant. Am J Transplant. 2020;20:333\u2013347","journal-title":"Am J Transplant"},{"key":"10703_CR17","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.3390\/cancers13194882","volume":"13","author":"F Pelizzaro","year":"2021","unstructured":"Pelizzaro F, Gambato M, Gringeri E, Vitale A, Cillo U, Farinati F, et al. Management of hepatocellular carcinoma recurrence after liver transplantation. Cancers. 2021;13:4882","journal-title":"Cancers"},{"key":"10703_CR18","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/tri.12372","volume":"27","author":"E Cholongitas","year":"2014","unstructured":"Cholongitas E, Mamou C, Rodr\u00edguez-Castro KI, Burra P. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int. 2014;27:1039\u20131049","journal-title":"Transpl Int"},{"key":"10703_CR19","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/TP.0000000000000965","volume":"100","author":"EK Geissler","year":"2016","unstructured":"Geissler EK, Schnitzbauer AA, Z\u00fclke C, Lamby PE, Proneth A, Duvoux C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. Transplantation. 2016;100:116\u2013125","journal-title":"Transplantation"},{"key":"10703_CR20","doi-asserted-by":"crossref","first-page":"604","DOI":"10.5009\/gnl15017","volume":"10","author":"Q Wei","year":"2016","unstructured":"Wei Q, Xu X, Wang C, Zhuang R, Zhuang L, Zhou L, et al. Efficacy and safety of a steroid-free immunosuppressive regimen after liver transplantation for hepatocellular carcinoma. Gut Liver. 2016;10:604\u2013610","journal-title":"Gut Liver"},{"key":"10703_CR21","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.hbpd.2019.05.006","volume":"18","author":"Q Lai","year":"2019","unstructured":"Lai Q, Iesari S, Finkenstedt A, Hoppe-Lotichius M, Foguenne M, Lehner K, et al. Hepatocellular carcinoma recurrence after acute liver allograft rejection treatment: a multicenter European experience. Hepatobiliary Pancreat Dis Int. 2019;18:517\u2013524","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10703_CR22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156127","volume":"11","author":"HT Mantel","year":"2016","unstructured":"Mantel HT, Westerkamp AC, Adam R, Bennet WF, Seehofer D, Settmacher U, et al. Strict selection alone of patients undergoing liver transplantation for hilar cholangiocarcinoma is associated with improved survival. PLoS ONE. 2016;11: e0156127","journal-title":"PLoS ONE"},{"key":"10703_CR23","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/TP.0000000000003212","volume":"104","author":"G Sapisochin","year":"2020","unstructured":"Sapisochin G, Javle M, Lerut J, Ohtsuka M, Ghobrial M, Hibi T, et al. Liver transplantation for cholangiocarcinoma and mixed hepatocellular cholangiocarcinoma: Working Group Report from the ILTS Transplant Oncology Consensus Conference. Transplantation. 2020;104:1125\u20131130","journal-title":"Transplantation"},{"key":"10703_CR24","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jhep.2019.11.020","volume":"72","author":"V Mazzaferro","year":"2020","unstructured":"Mazzaferro V, Gorgen A, Roayaie S, Droz Dit Busset M, Sapisochin G. Liver resection and transplantation for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72:364\u2013377","journal-title":"J Hepatol"},{"key":"10703_CR25","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.1245\/s10434-020-08682-5","volume":"27","author":"T Kitajima","year":"2020","unstructured":"Kitajima T, Hibi T, Moonka D, Sapisochin G, Abouljoud MS, Nagai S. Center experience affects liver transplant outcomes in patients with hilar cholangiocarcinoma. Ann Surg Oncol. 2020;27:5209\u20135221","journal-title":"Ann Surg Oncol"},{"key":"10703_CR26","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2012.04.008","volume":"143","author":"S Darwish Murad","year":"2012","unstructured":"Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012;143:88\u201398","journal-title":"Gastroenterology"},{"key":"10703_CR27","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s12885-016-2360-8","volume":"16","author":"N Heits","year":"2016","unstructured":"Heits N, Heinze T, Bernsmeier A, Kerber J, Hauser C, Becker T, et al. Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts. BMC Cancer. 2016;16:322","journal-title":"BMC Cancer"},{"key":"10703_CR28","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2147\/OTT.S297643","volume":"14","author":"W Yang","year":"2021","unstructured":"Yang W, Sun Y. Promising molecular targets for the targeted therapy of biliary tract cancers: an overview. Onco Targets Ther. 2021;14:1341\u20131366","journal-title":"Onco Targets Ther"},{"key":"10703_CR29","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3390\/ijms20030500","volume":"20","author":"C-E Wu","year":"2019","unstructured":"Wu C-E, Chen M-H, Yeh C-N. mTOR inhibitors in advanced biliary tract cancers. Int J Mol Sci. 2019;20:500","journal-title":"Int J Mol Sci"},{"key":"10703_CR30","doi-asserted-by":"crossref","first-page":"363","DOI":"10.6002\/ect.2018.0024","volume":"17","author":"F Dondorf","year":"2019","unstructured":"Dondorf F, Ute\u03b2 F, Fahrner R, Felgendreff P, Ardelt M, Tautenhahn HM, et al. Liver transplant for perihilar cholangiocarcinoma (Klatskin tumor): the essential role of patient selection. Exp Clin Transplant. 2019;17:363\u2013369","journal-title":"Exp Clin Transplant"},{"key":"10703_CR31","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/01.TP.0000164141.34293.6B","volume":"80","author":"S Cameron","year":"2005","unstructured":"Cameron S, Ramadori G, F\u00fczesi L, Sattler B, Gunawan B, M\u00fcller D, et al. Successful liver transplantation in two cases of metastatic gastrointestinal stromal tumors. Transplantation. 2005;80:283\u2013284","journal-title":"Transplantation"},{"key":"10703_CR32","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.3390\/cancers12102972","volume":"12","author":"Y Duan","year":"2020","unstructured":"Duan Y, Haybaeck J, Yang Z. Therapeutic potential of PI3K\/AKT\/mTOR pathway in gastrointestinal stromal tumors: rationale and progress. Cancers. 2020;12:2972","journal-title":"Cancers"},{"key":"10703_CR33","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/TP.0000000000003118","volume":"104","author":"T Hibi","year":"2020","unstructured":"Hibi T, Rela M, Eason JD, Line PD, Fung J, Sakamoto S, et al. Liver transplantation for colorectal and neuroendocrine liver metastases and hepatoblastoma. Working Group Report fom the ILTS Transplant Oncology Consensus Conference. Transplantation. 2020;104:1131\u20131135","journal-title":"Transplantation"},{"key":"10703_CR34","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ciresp.2016.08.007","volume":"95","author":"MC Pavel","year":"2017","unstructured":"Pavel MC, Fondevila Campo C, Molina Santos V, Diaz Lorca A, Garcia-Valdecasas Salgado JC. Normothermic ex vivo liver perfusion from donors after type 2 cardiac arrest. Cir Esp. 2017;95:301\u2013303","journal-title":"Cir Esp"},{"key":"10703_CR35","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387:968\u2013977","journal-title":"Lancet"},{"key":"10703_CR36","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/14656566.2018.1476492","volume":"19","author":"L Lee","year":"2018","unstructured":"Lee L, Ito T, Jensen RT. Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. Expert Opin Pharmacother. 2018;19:909\u2013928","journal-title":"Expert Opin Pharmacother"},{"key":"10703_CR37","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2021.693387","volume":"8","author":"M Finotti","year":"2021","unstructured":"Finotti M, Vitale A, Gringeri E, D\u2019Amico FE, Boetto R, Bertacco A, et al. Colon rectal liver metastases: the role of the liver transplantation in the era of the transplant oncology and precision medicine. Front Surg. 2021;8: 693387","journal-title":"Front Surg"},{"key":"10703_CR38","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1111\/tri.13981","volume":"34","author":"J Lanari","year":"2021","unstructured":"Lanari J, Hagness M, Sartori A, Rosso E, Gringeri E, Dueland S, et al. Liver transplantation versus liver resection for colorectal liver metastasis: a survival benefit analysis in patients stratified according to tumor burden score. Transpl Int. 2021;34:1722\u20131732","journal-title":"Transpl Int"},{"key":"10703_CR39","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/bjs.10651","volume":"105","author":"H Grut","year":"2018","unstructured":"Grut H, Solberg S, Seierstad T, Revheim ME, Egge TS, Larsen SG, et al. Growth rates of pulmonary metastases after liver transplantation for unresectable colorectal liver metastases. Br J Surg. 2018;105:295\u2013301","journal-title":"Br J Surg"},{"key":"10703_CR40","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jceh.2017.10.003","volume":"7","author":"NS Choudhary","year":"2017","unstructured":"Choudhary NS, Saigal S, Bansal RK, Saraf N, Gautam D, Soin AS. Acute and chronic rejection after liver transplantation: what a clinician needs to know. J Clin Exp Hepatol. 2017;7:358\u2013366","journal-title":"J Clin Exp Hepatol"},{"key":"10703_CR41","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/TP.0000000000002147","volume":"102","author":"M Charlton","year":"2018","unstructured":"Charlton M, Levitsky J, Aqel B, O\u2019Grady J, Hemibach J, Rinella M, et al. International Liver Transplantation Society Consensus Statement on immunosuppression in liver transplant recipients. Transplantation. 2018;102:727\u2013743","journal-title":"Transplantation"},{"key":"10703_CR42","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1111\/ajt.13909","volume":"16","author":"AJ Demetris","year":"2016","unstructured":"Demetris AJ, Bellamy C, H\u00fcbscher SG, O\u2019Leary J, Randhawa PS, Feng S, et al. 2016 Comprehensive update of the Banff Working Group on liver allograft pathology: introduction of antibody-mediated rejection. Am J Transplant. 2016;16:2816\u20132835","journal-title":"Am J Transplant"},{"key":"10703_CR43","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/ajt.12212","volume":"13","author":"H Kaneku","year":"2013","unstructured":"Kaneku H, O\u2019Leary JG, Banuelos N, Jennings LW, Susskind BM, Klintmalm GB, et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant. 2013;13:1541\u20131548","journal-title":"Am J Transplant"},{"key":"10703_CR44","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/tri.13763","volume":"33","author":"B Kovandova","year":"2020","unstructured":"Kovandova B, Slavcev A, Honsova E, Erhartova D, Skibova J, Viklicky O, et al. De novo HLA Class II antibodies are associated with the development of chronic but not acute antibody-mediated rejection after liver transplantation - a retrospective study. Transpl Int. 2020;33:1799\u20131806","journal-title":"Transpl Int"},{"key":"10703_CR45","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/TP.0000000000001651","volume":"101","author":"JM Neuberger","year":"2017","unstructured":"Neuberger JM, Bechstein WO, Kuypers DR, Burra P, Citterio F, De Geest S, et al. Practical recommendations for long-term management of modifiable risks in kidney and liver transplant recipients: a guidance report and clinical checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) group. Transplantation. 2017;101:S1-s56","journal-title":"Transplantation"},{"key":"10703_CR46","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.transproceed.2014.12.037","volume":"47","author":"H Kim","year":"2015","unstructured":"Kim H, Lee KW, Yi NJ, Lee HW, Choi Y, Suh SW, et al. Outcome and technical aspects of liver retransplantation: analysis of 25-year experience in a single major center. Transpl Proc. 2015;47:727\u2013729","journal-title":"Transpl Proc"},{"key":"10703_CR47","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.cld.2016.12.013","volume":"21","author":"J Berumen","year":"2017","unstructured":"Berumen J, Hemming A. Liver retransplantation: how much is too much? Clin Liver Dis. 2017;21:435\u2013447","journal-title":"Clin Liver Dis"},{"key":"10703_CR48","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.cld.2014.05.010","volume":"18","author":"WH Kitchens","year":"2014","unstructured":"Kitchens WH, Yeh H, Markmann JF. Hepatic retransplant: what have we learned? Clin Liver Dis. 2014;18:731\u2013751","journal-title":"Clin Liver Dis"},{"key":"10703_CR49","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1097\/TP.0000000000003825","volume":"105","author":"A Schlegel","year":"2021","unstructured":"Schlegel A, Foley DP, Savier E, Flores Carvalho M, De Carlis L, Heaton N, et al. Recommendations for donor and recipient selection and risk prediction: Working Group Report from the ILTS consensus conference in DCD liver transplantation. Transplantation. 2021;105:1892\u20131903","journal-title":"Transplantation"},{"key":"10703_CR50","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa2031532","volume":"384","author":"R van Rijn","year":"2021","unstructured":"van Rijn R, Schurink IJ, de Vries Y, van den Berg AP, Cortes Cerisuelo M, Darwish Murad S, et al. Hypothermic machine perfusion in liver transplantation - a randomized trial. N Engl J Med. 2021;384:1391\u20131401","journal-title":"N Engl J Med"},{"key":"10703_CR51","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/aor.14468","volume":"47","author":"D Ghinolfi","year":"2023","unstructured":"Ghinolfi D, Melandro F, Torri F, Esposito M, Bindi M, Biancofiore G, et al. The role of sequential normothermic regional perfusion and end-ischemic normothermic machine perfusion in liver transplantation from very extended uncontrolled donation after cardiocirculatory death. Artif Organs. 2023;47:432\u2013440","journal-title":"Artif Organs"},{"key":"10703_CR52","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/lt.25762","volume":"26","author":"K Ig-Izevbekhai","year":"2020","unstructured":"Ig-Izevbekhai K, Goldberg DS, Karp SJ, Foley DP, Abt PL. Immunosuppression in donation after circulatory death liver transplantation: can induction modify graft survival? Liver Transpl. 2020;26:1154\u20131166","journal-title":"Liver Transpl"},{"key":"10703_CR53","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s11894-023-00902-8","volume":"25","author":"OJ Haque","year":"2023","unstructured":"Haque OJ, Roth EM, Lee DD. Modern-day practice of DCD liver transplantation: controversies, innovations, and future directions. Curr Gastroenterol Rep. 2023;25:413\u2013420","journal-title":"Curr Gastroenterol Rep"},{"key":"10703_CR54","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","volume":"56","author":"LP Fried","year":"2001","unstructured":"Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146-156","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10703_CR55","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12916-016-0763-7","volume":"14","author":"R Pavasini","year":"2016","unstructured":"Pavasini R, Guralnik J, Brown JC, di Bari M, Cesari M, Landi F, et al. Short Physical Performance Battery and all-cause mortality: systematic review and meta-analysis. BMC Med. 2016;14:215","journal-title":"BMC Med"},{"key":"10703_CR56","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.arr.2015.12.003","volume":"26","author":"BJ Buta","year":"2016","unstructured":"Buta BJ, Walston JD, Godino JG, Park M, Kalyani RR, Xue QL, et al. Frailty assessment instruments: systematic characterization of the uses and contexts of highly-cited instruments. Ageing Res Rev. 2016;26:53\u201361","journal-title":"Ageing Res Rev"},{"key":"10703_CR57","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruy\u00e8re O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16\u201331","journal-title":"Age Ageing"},{"key":"10703_CR58","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/lt.23495","volume":"18","author":"P Tandon","year":"2012","unstructured":"Tandon P, Ney M, Irwin I, Ma MM, Gramlich L, Bain VG, et al. Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. Liver Transpl. 2012;18:1209\u20131216","journal-title":"Liver Transpl"},{"key":"10703_CR59","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/ctr.12629","volume":"29","author":"PW Underwood","year":"2015","unstructured":"Underwood PW, Cron DC, Terjimanian MN, Wang SC, Englesbe MJ, Waits SA. Sarcopenia and failure to rescue following liver transplantation. Clin Transplant. 2015;29:1076\u20131080","journal-title":"Clin Transplant"},{"key":"10703_CR60","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jhep.2017.11.030","volume":"68","author":"JLA van Vugt","year":"2018","unstructured":"van Vugt JLA, Alferink LJM, Buettner S, Gaspersz MP, Bot D, Darwish Murad S, et al. A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: a competing risk analysis in a national cohort. J Hepatol. 2018;68:707\u2013714","journal-title":"J Hepatol"},{"key":"10703_CR61","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13226","volume":"32","author":"J Kahn","year":"2018","unstructured":"Kahn J, Wagner D, Homfeld N, M\u00fcller H, Kniepeiss D, Schemmer P. Both sarcopenia and frailty determine suitability of patients for liver transplantation-a systematic review and meta-analysis of the literature. Clin Transplant. 2018;32: e13226","journal-title":"Clin Transplant"},{"key":"10703_CR62","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/jcsm.12095","volume":"8","author":"M Kalafateli","year":"2017","unstructured":"Kalafateli M, Mantzoukis K, Choi Yau Y, Mohammad AO, Arora S, Rodrigues S, et al. Malnutrition and sarcopenia predict post-liver transplantation outcomes independently of the Model for End-stage Liver Disease score. J Cachexia Sarcopenia Muscle. 2017;8:113\u2013121","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10703_CR63","doi-asserted-by":"crossref","first-page":"575","DOI":"10.21037\/hbsn-21-145","volume":"10","author":"G Lan","year":"2021","unstructured":"Lan G, Yu C, Huang Y. The adverse impact, assessment and management of sarcopenia in liver transplantation candidates and recipients. Hepatobiliary Surg Nutr. 2021;10:575\u2013578","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10703_CR64","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/lt.25669","volume":"26","author":"L Fozouni","year":"2020","unstructured":"Fozouni L, Mohamad Y, Lebsack A, Freise C, Stock P, Lai JC. Frailty is associated with increased rates of acute cellular rejection within 3 months after liver transplantation. Liver Transpl. 2020;26:390\u2013396","journal-title":"Liver Transpl"},{"key":"10703_CR65","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/jpen.1824","volume":"44","author":"DGA Williams","year":"2020","unstructured":"Williams DGA, Villalta E, Aronson S, Murray S, Blitz J, Kosmos V, et al. Tutorial: development and implementation of a multidisciplinary preoperative nutrition optimization clinic. JPEN J Parenter Enteral Nutr. 2020;44:1185\u20131196","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"10703_CR66","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3892\/mco.2016.1015","volume":"5","author":"B Gyawali","year":"2016","unstructured":"Gyawali B, Shimokata T, Honda K, Kondoh C, Hayashi N, Yoshino Y, et al. Muscle wasting associated with the long-term use of mTOR inhibitors. Mol Clin Oncol. 2016;5:641\u2013646","journal-title":"Mol Clin Oncol"},{"key":"10703_CR67","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/jcsm.12336","volume":"10","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, Duplany A, Moncollin V, Mouradian S, Goillot E, Mazelin L, et al. Lack of muscle mTOR kinase activity causes early onset myopathy and compromises whole-body homeostasis. J Cachexia Sarcopenia Muscle. 2019;10:35\u201353","journal-title":"J Cachexia Sarcopenia Muscle"}],"updated-by":[{"DOI":"10.1007\/s12072-024-10766-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000}}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10703-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-024-10703-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10703-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T21:02:48Z","timestamp":1739826168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-024-10703-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":67,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10703"],"URL":"https:\/\/doi.org\/10.1007\/s12072-024-10703-4","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,15]]},"assertion":[{"value":"30 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12072-024-10766-3","URL":"https:\/\/doi.org\/10.1007\/s12072-024-10766-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tommaso Maria Manzia, Barbara Antonelli, Amedeo Carraro, Grazia Conte, Nicola Guglielmo, Andrea Lauterio, Laura Mameli, Umberto Cillo, Luciano De Carlis, Giuseppe Tisone, Riccardo Volpes, and Massimo Del Gaudio have no conflicts of interest. Paolo De Simone has served as an advisory board member for Novartis, Astellas, and Chiesi. Stefano Fagiuoli is on the Advisory Board and Speaker\u2019s Bureau for AbbVie, Gilead Sciences, MSD, Novartis, Astellas, Bayer, Kedrion, and Intercept. Francesco Lupo served as an advisory board member for Novartis, Astellas, Biotest, and Chiesi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}